Peetz Christopher sold $192K of MIRM
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 1,973 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $97.56 ($0.19M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider behavior but does not, by itself, indicate a new fundamental development for the company.
Market read
Traders may briefly reassess sentiment around insider selling, but the 10b5-1 framing typically limits actionable signal.
What to watch
Compare this sale size/value to prior Form 4 activity and remaining holdings; also consider whether other contemporaneous catalysts (trial/regulatory) are absent/present.
Background
SEC Form 4 reports an officer/director insider transaction for Mirum Pharmaceuticals; the sale was executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Mirum Pharmaceuticals CEO Peetz Christopher sold 1,973 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low probability of sustained price impact; any reaction is likely muted and short-lived.
The filing is a routine insider transaction with stated 10b5-1 plan usage, reducing interpretability as a new negative catalyst.
Market effects
Minimal; single-company insider transaction without accompanying operational/regulatory/drug-trial updates.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated or sizable insider sales can still coincide with management’s risk management rather than bearish fundamentals—watch for pattern vs one-off.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction; CEO sold shares under a 10b5-1 plan.
- insiderPeetz Christopher
CEO/officer who executed the open-market sale disclosed in the filing.
